The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis

Claudio Silveira, Rubens Belfort, Cristina Muccioli, Gary N. Holland, Cesar G. Victora, Bernardo L. Horta, Fei Yu, Robert B. Nussenblatt

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS: Recurrences developed in four (6.6%) treated patients and in 15 (23.8%) controls (P = .01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume134
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Recurrence
Therapeutics
Sulfamethoxazole
Trimethoprim
Pharmaceutical Preparations
Tablets
Cicatrix
Brazil
Observation
Clinical Trials
Inflammation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Silveira, C., Belfort, R., Muccioli, C., Holland, G. N., Victora, C. G., Horta, B. L., ... Nussenblatt, R. B. (2002). The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. American Journal of Ophthalmology, 134(1), 41-46. https://doi.org/10.1016/S0002-9394(02)01527-1

The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. / Silveira, Claudio; Belfort, Rubens; Muccioli, Cristina; Holland, Gary N.; Victora, Cesar G.; Horta, Bernardo L.; Yu, Fei; Nussenblatt, Robert B.

In: American Journal of Ophthalmology, Vol. 134, No. 1, 2002, p. 41-46.

Research output: Contribution to journalArticle

Silveira, C, Belfort, R, Muccioli, C, Holland, GN, Victora, CG, Horta, BL, Yu, F & Nussenblatt, RB 2002, 'The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis', American Journal of Ophthalmology, vol. 134, no. 1, pp. 41-46. https://doi.org/10.1016/S0002-9394(02)01527-1
Silveira, Claudio ; Belfort, Rubens ; Muccioli, Cristina ; Holland, Gary N. ; Victora, Cesar G. ; Horta, Bernardo L. ; Yu, Fei ; Nussenblatt, Robert B. / The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. In: American Journal of Ophthalmology. 2002 ; Vol. 134, No. 1. pp. 41-46.
@article{8995f28c15344bc2a9d114ceb6bc94ee,
title = "The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis",
abstract = "PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS: Recurrences developed in four (6.6{\%}) treated patients and in 15 (23.8{\%}) controls (P = .01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.",
author = "Claudio Silveira and Rubens Belfort and Cristina Muccioli and Holland, {Gary N.} and Victora, {Cesar G.} and Horta, {Bernardo L.} and Fei Yu and Nussenblatt, {Robert B.}",
year = "2002",
doi = "10.1016/S0002-9394(02)01527-1",
language = "English (US)",
volume = "134",
pages = "41--46",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis

AU - Silveira, Claudio

AU - Belfort, Rubens

AU - Muccioli, Cristina

AU - Holland, Gary N.

AU - Victora, Cesar G.

AU - Horta, Bernardo L.

AU - Yu, Fei

AU - Nussenblatt, Robert B.

PY - 2002

Y1 - 2002

N2 - PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS: Recurrences developed in four (6.6%) treated patients and in 15 (23.8%) controls (P = .01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.

AB - PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS: Recurrences developed in four (6.6%) treated patients and in 15 (23.8%) controls (P = .01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.

UR - http://www.scopus.com/inward/record.url?scp=0036297399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036297399&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01527-1

DO - 10.1016/S0002-9394(02)01527-1

M3 - Article

VL - 134

SP - 41

EP - 46

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -